Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$3.03B |
 |
AmgenAMGN |
-$168M |
 |
Editas MedicineEDIT |
-$8.5M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Mayo Stephen | Mar 12, 2026 | Sell | 7,239 | $17.02 | $120,000 |
| Estepan Ian Michael | Dec 16, 2025 | Sell | 13,187 | $22.31 | $290,000 |
| Nicaise Claude | Mar 12, 2025 | Sell | 2,491 | $99.64 | $250,000 |
| Wigzell Hans Lennart Rudolf | Dec 12, 2024 | Sell | 10,500 | $124.84 | $1.3M |
| Boor Kathryn Jean | Dec 5, 2024 | Sell | 1,636 | $125.55 | $210,000 |
| Estepan Ian Michael | Aug 30, 2024 | Sell | 5,985 | $137.36 | $820,000 |
| Chambers Michael Andrew | Aug 16, 2024 | Buy | 18,284 | $134.06 | $2.5M |
| Chambers Michael Andrew | Aug 16, 2024 | Buy | 13,106 | $133.07 | $1.7M |
| Chambers Michael Andrew | Aug 16, 2024 | Buy | 5,648 | $134.66 | $760,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 17,581 | $162.65 | $2.9M |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 7,644 | $158.07 | $1.2M |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 4,168 | $161.82 | $670,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 3,840 | $163.53 | $630,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 2,549 | $164.52 | $420,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 2,200 | $159.14 | $350,000 |
| Arif Bilal | Jun 25, 2024 | Sell | 3,898 | $163.23 | $640,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 975 | $160.31 | $160,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 5,580 | $162.31 | $910,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 1,055 | $163.83 | $170,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 700 | $166.1 | $120,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 300 | $164.61 | $49,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 224 | $167.13 | $37,000 |
FAQ - Insider Transactions
The most recent insider transaction for Sarepta Therapeutics was conducted by Mayo Stephen, who sold 7,239 shares on March 12, 2026 at a price of $17.02 per share.
Chambers Michael Andrew has bought the most SRPT stock in the last 2 years, with a total value of $5M.
Brown Ryan Edward has sold the most SRPT stock in the last 2 years, with a total value of $6.3M.
The total value of insider transactions for Sarepta Therapeutics in the last 2 years is negative, amounting to -$6.3M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Sarepta Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
